Prevalence of pre-existing direct-acting antiviral agents resistance-associated variants in genotype 1 HCV/HIV co-infected patients / 上海交通大学学报（医学版）

ABSTRACT

Objective·To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infected patients.Methods·All NS3 and NSSB HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved from NCBI GenBank database.And sequences were aligned and analyzed using software MEGA 5.0.Results·In total,the overall prevalence of DAAs RAVs in NS3 region was high (26.06％ and 38.18％,respectively),no matter in genotype 1a or genotype 1b.In genotype 1a,the high prevalence of RAVs mainly presented in the position Q80 (8.45％).In genotype lb,S122 RAV was most observed (36.36％).It is worth noting that,RAVs in NS5B region were rare observed (0.77％) in this study,especially as no RAV was detected in any sequence of genotype 1a patients.Conclusion·The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients,suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.